{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:02:47Z","timestamp":1790726567142,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40262-018-0668-z","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T22:29:46Z","timestamp":1529360986000},"page":"1529-1538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist"],"prefix":"10.1007","volume":"57","author":[{"given":"Sylvie","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"key":"668_CR1","unstructured":"American Diabetes Association. Statistics about diabetes. 2017. \n                    http:\/\/www.diabetes.org\/diabetes-basics\/statistics\/\n                    \n                  . Accessed 18 Dec 2017."},{"key":"668_CR2","unstructured":"World Health Organization. Diabetes fact sheet. 2017. \n                    http:\/\/www.who.int\/mediacentre\/factsheets\/fs312\/en\/\n                    \n                  . Accessed 18 Dec 2017."},{"issue":"Suppl 1","key":"668_CR3","first-page":"S1","volume":"40","author":"American Diabetes Association","year":"2017","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142017. Diabetes Care. 2017;40(Suppl 1):S1\u2013142.","journal-title":"Diabetes Care"},{"key":"668_CR4","doi-asserted-by":"publisher","DOI":"10.4158\/EP16182.CS","author":"MJ Abrahamson","year":"2017","unstructured":"Abrahamson MJ, Barzilay JI, Blonde L, et al. AACE\/ACE comprehensive type 2 diabetes management algorithm\u20142017. Endocr Pract. 2017. \n                    https:\/\/doi.org\/10.4158\/EP16182.CS\n                    \n                  .","journal-title":"Endocr Pract"},{"issue":"4","key":"668_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"18","key":"668_CR6","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370\u201380.","journal-title":"J Med Chem"},{"issue":"11","key":"668_CR7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","volume":"56","author":"TC Marbury","year":"2017","unstructured":"Marbury TC, Flint A, Jacobsen JB, Derving Karsb\u00f8l J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56(11):1381\u201390.","journal-title":"Clin Pharmacokinet"},{"key":"668_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","volume":"104","author":"L Jensen","year":"2017","unstructured":"Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31\u201341.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"668_CR9","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"668_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jcph.443","volume":"55","author":"C Kapitza","year":"2015","unstructured":"Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel. J Clin Pharmacol. 2015;55(5):497\u2013504.","journal-title":"J Clin Pharmacol"},{"issue":"18","key":"668_CR11","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370\u201380.","journal-title":"J Med Chem"},{"key":"668_CR12","unstructured":"Victoza (liraglutide) [prescribing information]. Bagsvaerd: Novo Nordisk. 2017. \n                    http:\/\/www.novo-pi.com\/victoza.pdf\n                    \n                  . Accessed 8 Mar 2018."},{"key":"668_CR13","unstructured":"Trulicity (dulaglutide) [prescribing information]. Indianapolis: Eli Lily and Company. 2017. \n                    http:\/\/pi.lilly.com\/us\/trulicity-uspi.pdf\n                    \n                  . Accessed 8 Mar 2018."},{"issue":"1\u20132","key":"668_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijpharm.2008.01.015","volume":"356","author":"BR Gedulin","year":"2008","unstructured":"Gedulin BR, Smith PA, Jodka CM, et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm. 2008;356(1\u20132):231\u20138.","journal-title":"Int J Pharm"},{"issue":"2","key":"668_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258\u201366.","journal-title":"Diabetes Care"},{"issue":"4","key":"668_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275\u201386. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(18)30024-X\n                    \n                  .","journal-title":"Lancet Diabetes Endocrinol."},{"key":"668_CR17","unstructured":"Novo Nordisk. Semaglutide subcutaneous once-weekly treatment to improve glycemic control in adults with type 2 diabetes mellitus. Endocrinologic and Metabolic Drug Advisory Committee. 2017."},{"issue":"4","key":"668_CR18","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/dom.13186","volume":"20","author":"L Jensen","year":"2018","unstructured":"Jensen L, Kupcova V, Arold G, Pettersson J, Hjerpsted JB. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab. 2018;20(4):998\u20131005. \n                    https:\/\/doi.org\/10.1111\/dom.13186\n                    \n                  .","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"668_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"668_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahren","year":"2017","unstructured":"Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341\u201354.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"668_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355\u201366.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"668_CR22","unstructured":"Rodbar HW, Lingvay I, Reed J. Semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5) [poster no. 766]. In: 52nd European Association for the Study of Diabetes Annual Meeting; 13\u201316 Sep 2016; Munich."},{"issue":"19","key":"668_CR23","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"11","key":"668_CR24","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40262-017-0532-6","volume":"56","author":"H Hausner","year":"2017","unstructured":"Hausner H, Derving KJ, Holst AG, et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarain, atorvastatin, and digoxin in healthy subjects. Clin Pharmacokinet. 2017;56(11):1391\u2013401.","journal-title":"Clin Pharmacokinet"},{"key":"668_CR25","unstructured":"Ozempic [package insert]. Plainsboro: Novo Nordisk. 2017."},{"issue":"3","key":"668_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/dom.13120","volume":"20","author":"JB Hjerpsted","year":"2018","unstructured":"Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"668_CR27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"668_CR28","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460\u201370.","journal-title":"JAMA"},{"key":"668_CR29","unstructured":"Blendell J, Finlayson G, Buhl M, et al. Semaglutide reduced appetite and energy intake, improves control of eating, and provides weight loss in subjects with obesity [poster no. 23-OR]. In: American Diabetes Association Annual Meeting; 9\u201313 Jun 2017; San Diego."},{"key":"668_CR30","unstructured":"Company announcement. Novo Nordisk no. 50\/2017. Bagsvaerd: Novo Nordisk A\/S Investor Relation.\u00a02017."},{"issue":"4","key":"668_CR31","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsb\u00f8ll","year":"2018","unstructured":"Vilsb\u00f8ll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Sim\u00f3 R, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889\u201397. \n                    https:\/\/doi.org\/10.1111\/dom.13172\n                    \n                  .","journal-title":"Diabetes Obes Metab"},{"key":"668_CR32","unstructured":"Adlyxin (lixisenatide) [prescribing information]. Bridgewater: Sanofi-Aventis US LLC. 2016."},{"key":"668_CR33","unstructured":"Bydureon (exenatide) [prescribing information]. Wilmington: AstraZeneca Pharmaceuticals LP. 2017."},{"key":"668_CR34","unstructured":"Byetta (exenatide) [prescribing information]. Wilmington: AstraZeneca Pharmaceuticals. 2015."},{"key":"668_CR35","unstructured":"Ozempic (semaglutide) [prescribing information]. Bagsvaerd: Novo Nordisk. 2017."},{"key":"668_CR36","unstructured":"Tanzeum (albiglutide) [prescribing information]. Wilmington: GlaxoSmithKline. 2017."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0668-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0668-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0668-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T19:48:12Z","timestamp":1560887292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0668-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0668-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"19 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sylvie Hall, Diana Isaacs, and Jennifer N. Clements declare they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}